Objective, peer-reviewed reporting on therapeutic peptides, regulatory updates, clinical trial results, and scientific consensus. No hype. No product sales.
Articles tagged Semax.
Day 2 of the FDA PCAC meeting produced mixed results: Epitalon passed 7-4, Semax passed 8-5, and Emideltide was the only peptide voted down across both days, failing 6-7. Here is the full breakdown.
On July 23–24, the FDA's Pharmacy Compounding Advisory Committee will review seven popular peptides. We break down the agenda, the end of the Category 1 vs. Category 2 era, and the realistic odds for each substance.
Semax and Selank are two of the most popular central nervous system peptides in the biohacking community. Discover what the latest 2026 clinical science reveals about their mechanisms, benefits, and differences.
No articles match that search.